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Available online 24 October 2017More efficacious treatment regimens are needed for tuberculosis, however, drug development is impeded by a
lack of reliable biomarkers of disease severity and of treatment effect.We conducted a directed screen of host bio-
markers in participants enrolled in a tuberculosis clinical trial to address this need. Serum samples from 319 pro-
tocol-correct, culture-confirmed pulmonary tuberculosis patients treated under direct observation as part of an
international, phase 2 trial were screened for 70markers of infection, inflammation, andmetabolism. Biomarker
assays were specifically developed for this study and quantified using a novel, multiplexed
electrochemiluminescence assay. We evaluated the association of biomarkers with baseline characteristics, as
well as with detailed microbiologic data, using Bonferroni-adjusted, linear regression models. Across numerous
analyses, seven proteins, SAA1, PCT, IL-1β, IL-6, CRP, PTX-3 and MMP-8, showed recurring strong associations
with markers of baseline disease severity, smear grade and cavitation; were strongly modulated by tuberculosis
treatment; and had responses that were greater for patients who culture-converted at 8 weeks. With treatment,
all proteins decreased, except for osteocalcin, MCP-1 andMCP-4, which significantly increased. Several previous-
ly reported putative tuberculosis-associated biomarkers (HOMX1, neopterin, and cathelicidin) were not signifi-
cantly associated with treatment response. In conclusion, across a geographically diverse and large population of
tuberculosis patients enrolled in a clinical trial, several previously reported putative biomarkers were not signif-
icantly associatedwith treatment response, however, seven proteins had recurring strong associationswith base-
line radiographic and microbiologic measures of disease severity, as well as with early treatment response,
deserving additional study.pnahid@ucs
. This is an o© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Clinical trials1. Introduction
The lack of reliable surrogate markers of efficacy has hampered tu-
berculosis (TB) drugdevelopment. The current standard for use as a sur-
rogate endpoint in phase 2 studies remains focused on culture
conversion and the most studied is the two month culture status,
which has low sensitivity and modest specificity for predicting out-
comes after treatment completion.(Horne et al., 2010; Phillips et al.,
2016; Phillips et al., 2013; Nahid et al., 2011) Additionally, being depen-
dent on sputum, culture-based monitoring can be challenging to use in
extrapulmonary TB, and in patients with paucibacillary disease such asf.edu (P. Nahid).
pen access article underis seen in HIV-coinfected patients and in children.(Wallis et al., 2013;
Zumla et al., 2013) Both sputum volume and quality decreases in re-
sponse to treatment andmany patients cannot provide sputum samples
for culture after a fewweeks of treatment. The development of non-spu-
tum-based biomarkers of treatment response would represent an ad-
vance for individual monitoring of TB patients as well as serving as an
intermediate marker for use in TB drug development.
As an alternative to sputum-based monitoring, blood-based bio-
markers are appealing for several reasons. Blood is relatively easy to col-
lect and, unlike sputum, remains an available source for biomarker
measures throughout treatment. Blood-based markers of inflammation
and infections are also quantitative, and provide an opportunity to im-
prove predictive power by combining multiple biomarkers into predic-
tive biosignatures. Finally, blood-based markers of treatment responsethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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field without requiring sophisticated laboratory infrastructure, and
biosignatures that at baseline could determine disease severity would
also be valuable to clinical trialists and TB care providers for risk strati-
fication purposes, as alternatives to chest radiography, for example. Ef-
forts to identify host biomarkers predictive of treatment outcomes have
resulted in the identification of a number of biomarkers that change
during TB treatment, albeit most are described in observational cohorts
or smaller case-control studies.(Andrade et al., 2013; Azzurri et al.,
2005; Coussens et al., 2012; Djoba Siawaya et al., 2009; Djoba Siawaya
et al., 2008; Huang et al., 2014; Jayakumar et al., 2015; Lee and Chang,
2003; Mihret et al., 2013; Ostrowski et al., 2006) Such studies acknowl-
edge a variety of limitations including being single center studies, focus-
ing on single markers, using convenience samples, having modest
sample sizes, or relying on case-control designs.
In the work described herein, serum collected in a standardized
manner in a rigorously conducted clinical trial sponsored by the CDC-
funded TB Trials Consortium,was used to evaluate the efficacy and safe-
ty of a rifapentine-based regimen for drug-susceptible TB (Dorman et
al., 2012) Study participants received treatment under direct observa-
tion, thereby enhancing and carefully measuring adherence; an impor-
tant benchmark when assessing biomarkers of treatment effect. We
measured the concentration, and change in concentration, of 70 poten-
tial biomarkers associated with inflammatory, antimicrobial, T-cell and
acute phase responses to bacterial infections, and with tissue remodel-
ing at infection sites. These biomarkers were selected because they
have been published as indicators of TB disease and the clinical trial
samples provided an opportunity to reassess these associations across
diverse international sites (Andrade et al., 2013; Azzurri et al., 2005;
Coussens et al., 2012; Djoba Siawaya et al., 2009; Djoba Siawaya et al.,
2008; Huang et al., 2014; Jayakumar et al., 2015; Lee and Chang,
2003). Access to clinical trial-quality data allowed us to account for
changes in biomarker levels across disease phenotypes, regimens, and
geographic regions, in order to identify biomarkers associated with
treatment response.
2. Methods
2.1. Study Design and Population
The parent study was a CDC-sponsored clinical trial, Tuberculosis
Trials Consortium (TBTC) Study 29 (ClinicalTrials.gov Identifier
NCT00694629). This was a randomized phase 2 trial, comparing the an-
timicrobial activity and safety of a standard daily regimen containing ri-
fampin, to that of the experimental regimen with daily rifapentine
(10 mg/kg), both given with isoniazid, pyrazinamide and ethambutol
to adults with smear-positive, culture-confirmed pulmonary TB. All TB
treatmentwas administered 5 days/week anddirectly observed. All par-
ticipants underwent HIV testing. Information regarding the design, con-
duct, and results of TBTC Study 29 has been published (Dorman et al.,
2012). Out of a total of 531 participants in the parent study, 389 consec-
utively enrolled protocol-correct participants (rather than themodified
intention-to-treat population, since adherence may not be optimal in
this population) were included in this biomarker study. Of 389 partici-
pants, 319 had paired baseline and week 8 serum samples available
for biomarker testing. The parent trial excluded patients if they had re-
ceived N5 days of TB treatment in the preceding 6 months, however,
treatment of b5 days was permissible, and was noted in 60% of study
participants; the median number of days of treatment prior to enroll-
ment was 2 days, (IQR of 0 to 4 days). Detailed clinical, radiographic
and microbiologic data including sputum culture status at 8 weeks
and 12 weeks (determined on both liquid and solid media) were col-
lected in a standardized manner as part of the parent clinical trial and
used in biomarker analyses. Written informed consent was obtained
from all study participants for collection of serum for TB-related re-
search. In addition, the institutional review board at University ofCalifornia, San Francisco (UCSF) approved this ancillary study to assess
putative biomarkers of treatment response (approval #12-10360).
2.2. Specimen Collection
Blood was collected at enrollment (baseline), and after 8 weeks of
combination drug therapy, using Becton Dickinson Serum Separator
Tubes (BD Vacutainer® SST™ Tube, BD Diagnostics, Franklin Lakes, NJ,
USA). BD Vacutainer® SST™ Tubes were centrifuged within 2 h of col-
lection and processed according to manufacturer recommendations.
Collection, processing and storage of sera was conducted according to
a standardizedmanual of operating procedures that has been confirmed
to provide quality samples free of processing errors (Nahid et al., 2014).
Serum was aliquoted on site, frozen at−70 °C, and batch-shipped on
dry ice.
2.3. Multiplexed Immunoassays
A total of 70 biomarkers were measured in 14 multiplexed assay
panels using a sandwich immunoassay format (proteins) or a competi-
tive immunoassay format (neopterin), using electrochemiluminescence
(ECL) detection (Debad et al., 2004). The ECL assays employed consum-
ables and instrumentation fromMeso Scale Diagnostics, LLC (MSD). The
assay components for each panel included a MSD MULTI-ARRAY® 96-
well plate having an array of capture antibodies in each well, a set of la-
beled detection antibodies for each analyte in the panel (labeled with
theMSD SULFO-TAG™ ECL label), a combined calibration standard con-
taining amixture of the target analytes, an assay diluent and a detection
antibody diluent. For the neopterin competitive assay, a labeled
neopterin analog was used in the place of the labeled detection anti-
body. In total, 14 biomarker panel assayswere tested, sixMSD commer-
cial kits and eight custom assay panels that were newly developed for
this study (see Supplemental materials on Assay Methods).
2.4. Clinical Sample Tests
MSD received 500 μL of each sample at their core facility (Gaithers-
burg, MD)where assays were conducted with investigators and techni-
cians blinded to participant data. Each sample was tested in duplicate
with each of the 70 assays. Concentrationswere reported as the average
value of the duplicate measurements; values below the LOD were
assigned a concentration equal to the LOD. CVs were determined for
the biomarker levels measured in the control samples run on each
assay plate; themedian control CV (and IQR) across the different assays
was 10% (9%–13%).
2.5. Statistical Methods
Statistical analysis was conducted using the R statistical program-
ming language (version 3.2.3). Analysis of biomarkers used log10-trans-
formed concentrations. The Student's t-test was used for comparing
means across groups. Linear regression (using the “lm” function in R)
was used to determine the association of biomarker concentrations
with clinical variables and to adjust for potential covariates. The two-
sided t-statistic was used to determine the significance of regression co-
efficients with a threshold of p b 0.05 taken as statistically significant. To
account for multiple testing, we performed a Bonferroni correction for
the number of tests applied in each analysis.
Linear regression was used to identify associations of log10-trans-
formedbaseline biomarker levelswith baseline clinical indicators of dis-
ease severity at baseline: smear grade (grade = 1 vs. grade ≥ 2), chest
radiograph status (no cavities vs cavities; cavities ≤ 4 cm vs cavities
N4 cm; and extent of lung involvement b 50% vs lung involvement
N 50%) and MGIT time-to-detection (≤5 days vs N5 days). Two linear
models were employed: (i) an unadjusted model and (ii) a model that
adjusted for potential demographic and clinical covariates (gender,
Table 2
Association of baseline biomarker levels with baseline chest radiograph characteristics.
[A]
Biomarkers associated with presence of cavities at baseline
Unadjusted model Adjusted (demographics)
Assay Est (95%CI) P value AUC Est (95%CI) P value AUC
SAA1 1.97 (1.71, 2.28) 0.0000 0.65 1.81 (1.58, 2.08) 0.0000 0.65
CRP 1.74 (1.55, 1.94) 0.0000 0.65 1.60 (1.44, 1.78) 0.0000 0.64
IL-1β 1.56 (1.37, 1.77) 0.0005 0.62 1.42 (1.26, 1.58) 0.0023 0.61
MMP-8 1.54 (1.38, 1.71) 0.0001 0.63 1.42 (1.28, 1.57) 0.0006 0.61
PTX-3 1.39 (1.27, 1.53) 0.0004 0.61 1.27 (1.17, 1.39) 0.0040 0.61
MMP-9 1.37 (1.27, 1.48) 0.0001 0.63 1.31 (1.22, 1.42) 0.0004 0.61
sICAM-1 1.17 (1.12, 1.22) 0.0004 0.61 1.12 (1.08, 1.16) 0.0023 0.60
[B]
Biomarkers associated with cavities N 4 cm at baseline
Unadjusted model Adjusted (demographics)
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can) and study arm).
For each biomarker, the treatment effect for a given participant was
calculated as C8/C0; the ratio of the biomarker levels at week 8 (C8; con-
centration after treatment) relative to week 0 (C0; concentration at
baseline). Linear regression was used to examine the significance of
the association of the log10-transformed treatment effect with culture
conversion. Three models were used: (i) an unadjusted model; (ii) a
model that adjusted for demographic covariates, and (iii) an adjusted
model that included indicators of baseline disease severity (as described
above).
We also investigatedwhether biomarker combinationswere predic-
tive of week-8 culture status. The primary methodology employed was
L1 penalized (Lasso) logistic regression (R package glmnet), with ran-
dom forests also being deployed (R package random ForestSRC).
(Hastie et al., 2009).Assay Est (95%CI) P value AUC Est (95%CI) P value AUC
SAA1 1.90 (1.65, 2.19) 0.0000 0.65 1.62 (1.41, 1.86) 0.0005 0.62
IL-1β 1.77 (1.57, 2.00) 0.0000 0.65 1.48 (1.32, 1.65) 0.0006 0.62
CRP 1.67 (1.50, 1.87) 0.0000 0.64 1.45 (1.31, 1.62) 0.0004 0.61
IL-6 1.59 (1.41, 1.79) 0.0001 0.62 1.35 (1.20, 1.52) 0.0093 0.60
MMP-8 1.55 (1.39, 1.73) 0.0000 0.64 1.35 (1.22, 1.49) 0.0036 0.60
PTX-3 1.39 (1.27, 1.52) 0.0003 0.62 1.20 (1.10, 1.31) 0.0306 0.58
sICAM-1 1.30 (1.24, 1.35) 0.0000 0.70 1.21 (1.17, 1.25) 0.0000 0.68
E-Selectin 1.29 (1.21, 1.37) 0.0001 0.63 1.22 (1.15, 1.30) 0.0017 0.61
IL-2R 1.27 (1.20, 1.35) 0.0001 0.64 1.18 (1.12, 1.25) 0.0022 0.61
LBP 1.26 (1.18, 1.34) 0.0002 0.63 1.18 (1.11, 1.25) 0.0065 0.61
TNF-RI 1.17 (1.12, 1.22) 0.0003 0.62 1.13 (1.08, 1.17) 0.0045 0.61
[C]3. Results
The demographic and clinical characteristics of the 319 protocol-
correct trial participants included in biomarker analyses are shown in
Table 1. Three patients (1%) remained sputum culture positive at
16 weeks and were adjudicated to have failed treatment.
Using multiplexed ECL assays, we quantified the serum levels of 69
proteins and one metabolic marker. For a majority of these biomarkers
(62 of 70), the level was greater than twice the limit of detection for
at least 75% of the samples (Supplemental Table 1).Table 1
Demographic and clinical characteristics of the study population.
No. patients Number with stable sputum conversion on
solid and liquid media
(% of total) (% of category)
Characteristic At 8 weeks At 12 weeks At 16 weeks
All subjects 319 (100%) 209 (66%) 264 (83%) 316 (99.1%)
Gender
Female 107 (34%) 86 (80%) 93 (87%) 105 (98.1%)
Male 212 (66%) 123 (58%) 171 (81%) 211 (99.5%)
Age
0–20 17 (5%) 13 (76%) 16 (94%) 17 (100.0%)
21–40 203 (64%) 128 (63%) 169 (83%) 203 (100.0%)
41–60 80 (25%) 54 (68%) 63 (79%) 78 (97.5%)
61 19 (6%) 14 (74%) 16 (84%) 18 (94.7%)
Body mass index
BMI ≤ 18.5 97 (30%) 56 (58%) 80 (82%) 95 (97.9%)
BMI N 18.5 222 (70%) 153 (69%) 184 (83%) 221 (99.5%)
Location
N. America 109 (34%) 85 (78%) 99 (91%) 107 (98.2%)
Spain 24 (8%) 17 (71%) 19 (79%) 24 (100.0%)
S. Africa 64 (20%) 44 (69%) 54 (84%) 64 (100.0%)
Uganda 122 (38%) 63 (52%) 92 (75%) 121 (99.2%)
HIV status
Negative 284 (89%) 189 (67%) 235 (83%) 282 (99.3%)
Positive 35 (11%) 20 (57%) 29 (83%) 34 (97.1%)
Baseline smear
Low 114 (36%) 91 (80%) 102 (89%) 114 (100.0%)
High 205 (64%) 118 (58%) 162 (79%) 202 (98.5%)
Baseline chest x-Ray
No cavity 115 (36%) 84 (73%) 98 (85%) 115 (100.0%)
Cavity ≤ 4 cm 80 (25%) 54 (68%) 70 (88%) 79 (98.8%)
Cavity N 4 cm 124 (39%) 71 (57%) 96 (77%) 122 (98.4%)
Baseline MGIT960
TTD b= 5 days 82 (26%) 45 (55%) 64 (78%) 79 (96.3%)
TTD N 5 days 237 (74%) 164 (69%) 200 (84%) 237 (100.0%)
Study arm
Rifampin 151 (47%) 93 (62%) 124 (82%) 151 (100.0%)
Rifapentine 168 (53%) 116 (69%) 140 (83%) 165 (98.2%)
MGIT960 TTD refers to the time-to-detection for baseline liquid mycobacterium growth
indicator tube system (MGIT) 960 cultures. Sputum conversion indicates negative sputum
culture on both solid and liquid media at the specified time point.
Biomarkers associated with TB extent of disease on baseline chest radiograph
(N50% lung involvement)
Unadjusted model Adjusted (demographics)
Assay Est (95%CI) P value AUC Est (95%CI) P value AUC
IL-1β 2.42 (2.15, 2.72) 0.0000 0.73 2.00 (1.79, 2.23) 0.0000 0.70
IL-6 1.89 (1.67, 2.13) 0.0000 0.67 1.56 (1.38, 1.76) 0.0002 0.64
SAA1 1.87 (1.62, 2.16) 0.0000 0.65 1.55 (1.34, 1.79) 0.0025 0.62
PCT 1.78 (1.57, 2.02) 0.0000 0.65 1.46 (1.28, 1.66) 0.0039 0.61
IP-10 1.67 (1.50, 1.87) 0.0000 0.66 1.49 (1.34, 1.67) 0.0003 0.64
VEGF 1.66 (1.52, 1.82) 0.0000 0.68 1.49 (1.37, 1.63) 0.0000 0.65
IFN-γ 1.63 (1.44, 1.85) 0.0001 0.63 1.42 (1.26, 1.60) 0.0031 0.60
CRP 1.62 (1.45, 1.81) 0.0000 0.65 1.33 (1.19, 1.49) 0.0097 0.59
I-TAC 1.59 (1.40, 1.80) 0.0002 0.62 1.28 (1.15, 1.42) 0.0245 0.59
CXCL9 1.57 (1.44, 1.72) 0.0000 0.66 1.43 (1.31, 1.56) 0.0000 0.64
MIP-3α 1.55 (1.38, 1.73) 0.0001 0.63 1.40 (1.26, 1.55) 0.0016 0.62
IL-2R 1.52 (1.44, 1.61) 0.0000 0.73 1.36 (1.29, 1.44) 0.0000 0.70
MMP-8 1.48 (1.33, 1.65) 0.0003 0.61 1.24 (1.12, 1.38) 0.0421 0.56
E-Selectin 1.48 (1.39, 1.57) 0.0000 0.70 1.38 (1.29, 1.47) 0.0000 0.68
PTX-3 1.46 (1.33, 1.59) 0.0000 0.64 1.20 (1.10, 1.31) 0.0357 0.58
Osteopontin 1.41 (1.33, 1.48) 0.0000 0.71 1.26 (1.20, 1.33) 0.0000 0.67
MMP-1 1.36 (1.25, 1.49) 0.0005 0.62 1.19 (1.09, 1.30) 0.0457 0.57
uPAR 1.34 (1.28, 1.41) 0.0000 0.69 1.28 (1.22, 1.34) 0.0000 0.67
sICAM-1 1.34 (1.29, 1.40) 0.0000 0.73 1.24 (1.20, 1.29) 0.0000 0.71
MMP-9 1.32 (1.22, 1.42) 0.0005 0.62 1.18 (1.09, 1.28) 0.0364 0.57
Granzyme-B 1.28 (1.20, 1.37) 0.0003 0.63 1.17 (1.10, 1.25) 0.0148 0.60
LBP 1.27 (1.19, 1.35) 0.0002 0.63 1.17 (1.10, 1.25) 0.0114 0.60
TNF-RII 1.21 (1.15, 1.28) 0.0005 0.62 1.12 (1.06, 1.19) 0.0387 0.58
Neopterin 1.20 (1.15, 1.26) 0.0000 0.63 1.20 (1.15, 1.25) 0.0001 0.63
TNF-RI 1.19 (1.14, 1.25) 0.0000 0.64 1.12 (1.08, 1.17) 0.0077 0.60
LBP 1.27 (1.19, 1.35) 0.0002 0.63 1.17 (1.10, 1.25) 0.0114 0.60
The estimated association (Est) is 10coeff, where coeff is the coefficient of a linearmodel for
the effect of the indicated baseline radiographic characteristics on log10 transformed base-
line biomarker levels. The Est value can be interpreted as the expected factor change in
baseline biomarker level for patients with [A] cavities relative to patients with no cavities;
[B] cavities N 4 cm relative to patients with cavities b 4 cm; [C] lung involvement N 50% rel-
ative to patients with lung involvement b 50%. The tables show values for an unadjusted
model as well as a model that is adjusted for demographic covariates (gender, age, BMI,
HIV status, region (Africa vs. Not-Africa) and study arm).The AUC value for ROC curves
is a non-parametric indicator of effect size, comparing thedistributions of biomarker ratios
for the two outcome classes (either unadjusted or adjusted for the covariates). Only bio-
markers with statistically significant associations (p b 0.05/62 assays = 0.0008) in at
least one of the models are shown.
Table 3
Association of baseline biomarker levels with baseline microbiological characteristics.
[A]
Smear grade N 1 at baseline
Unadjusted model Adjusted (demographics)
Assay Est (95%CI) P value AUC Est (95%CI) P value AUC
SAA1 1.68 (1.45, 1.95) 0.0004 0.62 1.52 (1.32, 1.74) 0.0027 0.60
IL-1β 1.57 (1.38, 1.78) 0.0004 0.62 1.39 (1.24, 1.56) 0.0033 0.60
IL-6 1.52 (1.34, 1.72) 0.0008 0.62 1.37 (1.22, 1.54) 0.0060 0.59
PTX-3 1.49 (1.36, 1.63) 0.0000 0.64 1.37 (1.26, 1.48) 0.0002 0.63
TNF-RI 1.19 (1.14, 1.24) 0.0001 0.62 1.15 (1.11, 1.20) 0.0006 0.61
[B]
MGIT time-to-detection
Unadjusted model Adjusted (demographics)
Assay Est (95%CI) P value AUC Est (95%CI) P value AUC
IFN-γ 1.82 (1.56, 2.12) 0.0001 0.67 1.48 (1.28, 1.70) 0.0062 0.63
IL-15 1.27 (1.19, 1.34) 0.0001 0.67 1.19 (1.12, 1.27) 0.0038 0.63
The estimated association (Est) is 10coeff, where coeff is the coefficient of a linearmodel for the effect of the indicated baselinemicrobiological characteristics on log10 transformed baseline
biomarker levels. The Est value can be interpreted as the expected factor change in baseline biomarker level for patients with [A] baseline smear grade N 1 relative to patients with smear
grade b 1; [B] baselineMGIT time-to-detection ≤ 5 days relative to patientswithMGIT time-to-detection N 5 days. The tables show values for an unadjustedmodel aswell as amodel that is
adjusted for demographic covariates (gender, age, BMI, HIV status, region (Africa vs. Not-Africa) and study arm). The AUC value for ROC curves is a non-parametric indicator of effect size,
comparing the distributions of biomarker ratios for the two outcome classes (either unadjusted or adjusted for the covariates). Only biomarkerswith statistically significant associations (p
b 0.05/62 assays = 0.0008) in at least one of the models are shown.
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b25% of the samples. We excluded these assays – GM-CSF, IL-1α, IL-2,
IL-4, IL-12p70, IL-13, IFN-2α and IFNβ – from further analysis.
3.1. Baseline Biomarkers Associated With Baseline Clinical Characteristics
Linear models were used to measure the association of biomarker
levels with disease severity at baseline, with and without correction
for demographic covariates. Tables 2 and 3 show the biomarkers that
had a coefficient significantly different than 0 in at least one of the
models. For the unadjusted model, we found biomarkers with signifi-
cant associations with each of the indicators. Adjustment for demo-
graphic covariates tended to decrease the significance of the
associations. Even after adjustment, however, some biomarkers
retained significant associations for all indicators except MGIT time-
to-detection. Fig. 1 shows the baseline biomarker levels against disease
classification group, for six biomarkers (SAA1, CRP, IL-1β, IL-6, PTX-3
andMMP-8) that tended to have themost significant increases in base-
line levels with increases in disease severity indicators.
The analysis of baseline biomarker levels was repeated after stratifi-
cation for HIV status. Limiting analysis to only HIV negative patients did
not significantly change the identified biomarkers or the strengths of
the measured associations with baseline clinical characteristics (data
not shown). The study was not sufficiently powered for identifying bio-
markers associatedwith baseline clinical characteristics for theHIV pos-
itive subjects, however, qualitatively the association of the two acute
phase proteins SAA1 and CRP with baseline clinical characteristics ap-
peared to be much weaker in the HIV positive subjects relative to the
HIV negative subjects. For example, for HIV negative subjects, SAA1
was 2.09-fold higher (CI: 1.79 to 2.43) in subjects with cavities at base-
line and 1.77-fold higher (CI: 1.51 to 2.07) in subjects with sputum
smear grades of 2 or higher, while for HIV positive subjects the mea-
sured increases in SAA1 associated with these two indicators were
only 1.44-fold (CI: 0.99 to 2.11) and 1.16-fold (0.78 to 1.71),
respectively.
3.2. Effect of Treatment on Biomarker Levels
Fig. 2 shows the treatment effect for all biomarkers across all pa-
tients. Qualitatively, a large number of biomarkers appear to be influ-
enced by treatment and have a preponderance of points with ratiosabove or below one. The spread in the effect for different subjects, how-
ever, is large and for some assays covers more than a factor of ten. Bio-
markers with significant treatment effects were selected based on two
criteria (Supplemental Table 2). First, the geometric average treatment
effect was significantly different from one. Second, the inter-quartile
range (IQR) did not include the null result (i.e., C8/C0 = 1). Most of
the selected biomarkers (23 of 26) exhibited, on average, decreases in
levels with treatment; only three biomarkers increased with treatment.
Three of the largest average decreases with treatment were observed
for the acute phase proteins SAA1, CRP and LBP,with the largest average
decrease (~ten-fold) exhibited by SAA1. Large decreases were also ob-
served for cytokines associated with host inflammatory response (IL-
6, IL-1β and IL-22), and biomarkers of tissue reorganization and repair
(MMP-1, MMP-8 and VEGF). The largest increase in biomarker levels
with treatment was observed for osteocalcin (~1.6-fold), a bone-de-
rived biomarker with a role in bone synthesis and glucose metabolism.
Stratification by HIV status indicated that the markers showing
changes with treatment and the sizes of themeasured treatment effects
were not significantly different for the HIV positive and negative sub-
groups (data not shown). One exception was LAG-3. For the HIV nega-
tive subjects, LAG-3 demonstrated a relatively modest 1.18-fold
increase in average biomarker level with treatment (CI: 1.10 to 1.27).
However, in the HIV positive group, a significantly larger 1.90-fold in-
crease was observed (CI: 1.64 to 2.39).
3.3. Biomarkers Associated With Microbiologic Treatment Response
Fig. 3 shows the ratio of week-8 andweek-0 biomarker levels for the
top 25 biomarkers listed in Supplemental Table 2 across all patients, col-
oring the points based on culture conversion status at week 8. Qualita-
tively, the change in biomarker levels with treatment tends to be
greater for the patients that achieve culture conversion, especially for
the biomarkers that are most affected by treatment. However, there is
considerable overlap in the distributions.
The associations of biomarker treatment response with week-8 cul-
ture status for the six biomarkers with the strongest changes after treat-
ment (the top six biomarkers in Supplemental material Table 2) are
shown in Supplemental Table 3. Three biomarkers with strong re-
sponses to treatment (SAA1, CRP and IL-1β) were the only biomarkers
that also showed an association with week-8 culture status in at least
one of the models that met our criteria for significance. These
Fig. 1. Box and whisker plots showing the baseline levels of six biomarkers as a function of five indicators of baseline disease state: presence of cavities in chest x-ray, presence of cavities
N4 cm, lung involvement N 50%, smear grade (≤1 vs ≥2) and time-to-detection (≤5 days vs N5 days) for MGIT cultures. The asterisks indicate that the difference between two groups is
significant (p b 0.05/62 assays = 0.0008).
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mean ratio of week-8 to baseline biomarker levels for SAA and CRP
were almost two-fold higher for converted patients, relative to non-
converted patients. The three additionalmarkers listed in Supplemental
Table 3 (IL-6, MMP-8 and IFN-γ) also showed an apparent association
with week-8 culture status in the expected direction, but did not
achieve our criteria for significance. For four of the six biomarkers(SAA1, IL-1β, IL-6 andMMP-8), the strength of the association increased
and the p value decreased with the addition of covariates to the model.
Analyzing the HIV positive and negative subjects separately did not
change the identity of the biomarkers with the strongest associations
with week-8 culture status.
Whereas week-8 culture conversion was associated with ~two-fold
increase in the effect of treatment on levels of SAA1 and CRP, the
Fig. 2. Effect of TB treatment on biomarker levels. The plot shows the ratio of post-treatment (week 8) to baseline (week 0) biomarker levels for each biomarker in each study subject. The
assays are ordered based on the magnitude of the treatment effect. Asterisks indicate the effect is statistically significant (p b 0.05/62 assays = 0.0008).
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small relative to the overall variation of the treatment effect within
each group. For this reason, the predictive ability of any individualFig. 3. Association of biomarker treatment effect with sputum culture conversion status at wee
levels for the 25 biomarkers with the strongest treatment effects (the top 25 assays in Suppl
status at week 8 (blue = converted, red = non-converted). For each biomarker and group, a
significant association with culture status (p b 0.05/62 biomarkers = 0.0008) are marked withassay for week-8 culture status is likely to be relatively weak. The area
under curve (AUC) values for receiver operating characteristic (ROC)
analysis can be used as a non-parametric indicator of effect size. Thek 8. The plot shows the ratio of post-treatment (week 8) to baseline (week 0) biomarker
emental Table 2). Points are separated and colored based on sputum culture conversion
horizontal line segment indicates the median biomarker value. The biomarkers with a
an asterisk.
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0.65 depending on the model used.
For the six biomarkers with the strongest response to treatment, we
compared the strength of the association of biomarker response with
week-8 culture status, week-12 culture status andweek-8 cough status
(Fig. 4). Analysis of the association of the biomarkers withweek-12 cul-
ture status showed trends thatwere similar to those described above forFig. 4.Box andwhisker plots showing themagnitude of the treatment effect for six biomarkers (
outcome variables: week 8 culture conversion status, week 12 culture conversion status, and pr
groups is significant (p b 0.05/62 assays = 0.0008).week-8 culture status, although the strength of the associations was
weaker and the p values did not meet our criteria for significance. For
example, the increase in treatment response (unadjusted for covariates)
with week-8 culture conversion was 1.7-fold (p= 0.0001) for CRP and
1.8-fold (p = 0.0009) for SAA1, but the association with week-12 cul-
ture conversion was 1.6-fold (p = 0.040) for CRP and 1.6-fold (p =
0.010) for SAA1.the ratio ofweek 8 andweek 0 biomarker levels) after grouping subjects according to three
esence/absence of cough at 8weeks. The asterisks indicate that the difference between two
119G.B. Sigal et al. / EBioMedicine 25 (2017) 112–121Association of the biomarker response to treatment with week-8
cough status was weak. As with culture status, the largest increases in
the biomarker response to treatment with absence of cough at
8 weeks (unadjusted for covariates) were observed for SAA1 (1.2-fold,
p= 0.37) and CRP (1.3-fold, p= 0.048).
Use of biomarker combinations as predictors of week-8 culture sta-
tus did not reveal any compelling signatures. Themodest AUCvalues re-
ported above for individual biomarkers were only incrementally
improved when signatures were derived using L1 penalized logistic re-
gression. For example, using cross-validated AUC as a predictive model
performancemetric and invoking the “1 SE rule” for determiningmodel
size and restricting analysis to HIV negative subjects yields a set of four
markers (CRP, IL_10,MMP_3 and IFN_g). However, the attendant cross-
validated AUC is only 0.63. While a 13 marker model was optimal,
achieving a value of 0.66, the variability associated with this estimate
make the stability of the corresponding signature questionable. Similar-
ly, random forest-based classification did not produce improved predic-
tive performance. Analysis of biomarker associations with treatment
failure was not feasible as only three trial participants (1%) failed
treatment.4. Discussion
In this study, we identified biomarkers associated with radiographic
and microbiologic measures of severity, as well as biomarkers associat-
ed with treatment response. Seven baseline biomarkers were signifi-
cantly associated with the presence or absence of cavities at
enrollment. The strongest effect was observed for the acute phase pro-
tein SAA1 (serum amyloid protein A), which showed a two-fold in-
crease at baseline in patients with cavities, as compared to patients
without cavities. The other proteins associated with cavitation included
the inflammatory cytokine IL-1β, the tissue-remodeling factor MMP-8
(matrix metalloproteinase 8) and the cell migration factor sICAM-1
(soluble intercellular cell adhesion molecule 1). Interestingly, the num-
ber of biomarkers associatedwith baseline TBdisease increasedwith in-
creasing disease severity: seven biomarkers were associated with the
presence of any cavities, 11 biomarkers associated with the presence
of cavities larger than 4 cm, and 26 biomarkers associated with ≥50%
of lung involvement. The associations between serum biomarkers and
severity of lung injury is plausible given production of these markers
in the lung has also been reported. For instance, SAA1 is expressed in
the lung, and has been associatedwith lung injury aswell as lung cancer
(Lopez-Campos et al., 2013; Baba et al., 1992). Similarly, the collectin
Pentraxin 3 can both be produced in lung endothelial cells in response
to IL-1 (Pauwels et al., 2010) or in lung fibroblasts in response to TNF-
α (Mantovani et al., 2013) and is associated with pulmonary fibrosis
(Pilling et al., 2015). VEGF is expressed by epithelial cells as well as by
M. tuberculosis-infected macrophages, and has been implicated in gran-
uloma-associated angiogenesis (Polena et al., 2016). Finally, elevated
levels of alpha-defensin are associated with pulmonary fibrosis
(Mukae et al., 2002; Sakamoto et al., 2015a; Sakamoto et al., 2015b).
Taken together, these data suggest that selected markers measured in
serum reflect both the burden of microbial infection and the degree of
lung injury.
Biomarker associations with baseline measures of microbiologic
burden, namely smear grade and MGIT time-to-detection, were also
evaluated. We identified five biomarkers, SAA1, IL-1β, IL-6, PTX-3 and
TNF-RI, that had significant associations with smear grade. These bio-
markers were also among those that had the strongest associations
with more extensive disease on chest radiograph (described above).
Two additional biomarkers, IFN-γ and IL-15, were associated with
MGIT time-to-detection, andwere distinct from the fivemarkers associ-
ated with smear grade. The identification of serummarkers with strong
associations with baseline bacillary burden raises the possibility for
rapid point-of-care tests that could inform decisions at the time oftreatment initiation in terms of regimen composition and duration,
allowing for potential individualization of care.
On treatment, themajority of biomarkers declined significantly, sug-
gesting aberrant levels at baseline that return to normal as the disease is
treated, bacterial burden declines and lung injury resolves. Importantly,
we also found that several previously reported putative TB-associated
biomarkers (HOMX1, neopterin, and cathelicidin)were not significantly
associated with treatment response. The biomarkers with the strongest
treatment responses were SAA1, CRP, IL-6, MMP-8, and IL-1β, all of
whichwere also linked to disease severity andmeasures of baseline ba-
cillary burden, providing additional evidence that these markers are in-
dicators of disease state at time of diagnosis and during the course of
treatment. Treatment also decreased alpha-defensin levels, not previ-
ously reported in TB, although predicted by gene expression studies
(Maertzdorf et al., 2012). Plasma heme oxygenase-1 (HOMX1) has pre-
viously been reported to have a strong response to TB treatment,
(Andrade et al., 2013) but we found little change in HOMX1 levels
with treatment. Neopterin has also been reported to decrease signifi-
cantly with treatment; (Turgut et al., 2006) in our study we did not
see a large change in neopterin, but this result may be related to differ-
ences in timing of sample collection, as prior reports found that
neopterin levels return to baseline levels only after six months of treat-
ment. Whereas plasma protein 10 (IP-10)/CXCL10 has previously been
reported to be useful in monitoring patients in smaller studies,
(Azzurri et al., 2005; Wergeland et al., 2015; Kabeer et al., 2011) it
was not strongly associated with treatment effect in our analyses, al-
though higher levels were noted with greater TB extent of disease on
baseline chest radiograph. Cathelicidin and vitamin D binding protein
(VitD-BP) assays were developed for this study given the important
role of Vitamin D processing in TB disease, (Yamshchikov et al., 2010)
but we found little association with treatment response for these
markers. The biomarkers that had the strongest associations with
week-8 culture status, SAA1, CRP, IL1β, IL6, MMP-8 and IFN-γ, over-
lapped with the biomarkers that had the strongest associations with
baseline disease status, as well as the largest changes with treatment.
However, of these six biomarkers only three, SAA1, CRP and IL-1β, had
associations that met our criteria for significance, yet multivariate re-
gression models, employingmultiple biomarkers, did not identify com-
binations with high predictive utility for week-8 culture conversion.
Moreover, analysis of biomarker associations with treatment failure
was not feasible as only three trial participants (1%) failed treatment.
Three biomarkers showed increasing levels during treatment:
osteocalcin, MCP-1 and MCP-4. The increase in MCP-1 with treatment
has been previously noted (Djoba Siawaya et al., 2009). The reported
role of MCP-1 and MCP-4 (or monocyte chemoattractant proteins 1
and 4) as attractants for monocytes and T cells, cell types involved in
granuloma formation, provides a plausible mechanism by which levels
of these chemokines increase in response to treatment (Saunders and
Britton, 2007). The increase in osteocalcin with TB treatment is a new
finding, however, and the mechanism for this relationship is not clear.
Osteocalcin is an osteoblast-specific bone matrix protein involved in
bone formation, and has been found to be involved in insulin regulation,
(Wei and Karsenty, 2015) suggesting that osteocalcinmay play a role in
metabolic control during TB infection. Alternatively, osteocalcin levels
may be related to pathogen clearance (Das et al., 2013; Garhyan et al.,
2015). This is conceivable given reports that M. tuberculosis survival
post-therapymay involve infection of CD271(+) bonemarrow-mesen-
chymal stem cells, which may act as a protective intracellular niche for
M. tuberculosis persistence, and given that toll-like receptor stimulation
of osteoclast precursors inhibit their differentiation into non-inflamma-
tory mature osteoclasts during microbial infection, instead maintaining
the phagocytic activity of the precursor cells (Takami et al., 2002).
Our study has limitations. First, long-term outcomes of interest (re-
lapse versus durable cure) were not a component of the parent phase 2
trial, and our analyses were focused on biomarker associations with
baseline severity and microbiologic indicators of treatment effect only.
120 G.B. Sigal et al. / EBioMedicine 25 (2017) 112–121An evaluation of the most promising biomarkers we discovered should
be pursued as part of clinical trials with long-term follow-up. Second,
we were limited in our ability to explore the dynamics of biomarker
change given two time points for serum collection. An assessment of
the best performingmarkers in our study, across additional time points
would improve our understanding of the predictive performance of
these biomarkers. Third, the parent trial allowed for TB treatment
prior to the randomization visit when serum was collected and study
drugs initiated. This may have impacted baseline biomarker levels,
however, in sensitivity analyses limited to participants with no pre-
treatment, the biomarkerswith the strongest associationswith baseline
severity and treatment effect remained the same.
In conclusion, across 70 host biomarkers evaluated in a large and di-
verse population of TB patients enrolled in a clinical trial, we found that
several previously reported putative TB-associated biomarkers
(HOMX1, neopterin, and cathelicidin) were not significantly associated
with treatment response. However, across numerous analyses we did
identify seven recurring biomarkers that 1) were associated with base-
line disease severity, 2) were strongly modulated by TB treatment, and
3) had treatment responses thatwere greater for patients thatwere cul-
ture-converted at 8 weeks. These recurring biomarkers included acute
phase proteins (SAA1, PTX-3, PCT and CRP); inflammatory cytokines
(IL-1β and IL-6); and a factor associated with tissue reorganization
(MMP-8). These biomarkers may provide blood-based targets both for
determiningbaselinedisease severity and formonitoringdisease during
treatment; they warrant examination in patient cohorts with follow-up
that captures long-term outcomes of failure and relapse.
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